Risk Factors for Mortality in Mechanically Ventilated Patients with COVID-19 in a Mississippi Community Health System

S. Ijlal Babar, MD, Ashley E. Hawthorne, PharmD, BCCCP, and Maggie R. Clarkson, RN, MSN

Objective: To evaluate differences between survivors versus nonsurvivors undergoing mechanical ventilation for coronavirus disease 2019 (COVID-19)–associated respiratory failure at two community medical centers.

Methods: This was a multicenter, retrospective cohort analysis of all adult patients mechanically ventilated for COVID-19–associated respiratory failure in two community hospital intensive care units in southern Mississippi from March 15, 2020 through October 10, 2020.

Results: Among 56 patients requiring mechanical ventilation, the mortality rate was 75% (42/56). Expired patients were intubated later (2 vs 5 days, 95% confidence interval [CI] 6.314–0.8041, \( P = 0.0983 \)), had lower PaO2:FiO2 ratios (65 vs 77.5 mm Hg, 95% CI 36.08–59.03, \( P = 0.6305 \)), and tolerated lower levels of positive end-expiratory pressure (7.9 vs 12.6 cm H2O, 95% CI 0.1373–6.722, \( P = 0.0415 \)) at the time of intubation.

Conclusions: Our results suggest that earlier intubation may be associated with reduced mortality in patients with COVID-19-associated respiratory failure and should be further evaluated in the form of a randomized controlled trial.

Key Words: COVID-19, critical care, endotracheal intubation, respiration, SARS-CoV-2

Critically ill patients with coronavirus disease 2019 (COVID-19) requiring mechanical ventilation have a mortality rate of approximately 56%.1 We recently published our experience with hospitalized COVID-19 patients at the community hospital level, which showed that our outcomes were similar to those at larger centers.2 This retrospective study was designed to evaluate overall differences between survivors and nonsurvivors requiring mechanical ventilation for COVID-19 respiratory failure in two community hospital intensive care units (ICUs). Differences in timing of intubation and ventilator parameters were specifically evaluated.

Methods

This multicenter, retrospective cohort study includes all hospitalized adult patients with COVID-19 requiring mechanical ventilation at both campuses of the Singing River Health System in South Mississippi between March 15 and October 10, 2020. All patients tested positive for COVID-19 by reverse-transcriptase polymerase chain reaction (RT-PCR). This study was approved by the Singing River Health System Institutional Review Board (Registration 00004249).

We compared demographics and ventilator parameters of survivors and non-survivors with evaluate differences in timing of intubation in relation to the date of hospital admission, date of ICU admission, and date of COVID-19 diagnosis and compared the duration of mechanical ventilation before either extubation or death.

Continuous variables were reported as means and standard deviations or medians and interquartile ranges and analyzed with the Student \( t \) test or the Mann-Whitney test, respectively. Categorical variables were reported as frequencies and analyzed with the \( \chi^2 \) or the Fisher exact test, depending on the number of variables per cell. Statistical analyses were performed using GraphPad Prism software (GraphPad Software, San Diego, CA).

Results

A total of 56 patients required mechanical ventilation during the study period, with a mortality rate of 75% (Table 1). Comparisons

Key Points
- Patients intubated for coronavirus disease 2019–associated respiratory failure were separated into two groups (survivors and nonsurvivors) and differences in ventilator parameters and timing of intubation were evaluated.
- Clinically significant differences in PaO2:FiO2 ratios were observed on the day of intubation in survivors versus nonsurvivors.
- The timing of intubation was observed to be clinically significant, with survivors being intubated a median of 3 days earlier than nonsurvivors.
of demographics and comorbidities did not differ between groups, with the exception of a higher percentage of male patients in the nonsurvivors (29% vs 62%, \( P < 0.0001 \)). The patients in this cohort were severely hypoxemic, with a median PaO\(_2\):FiO\(_2\) ratio of 66.5 on day 1 of intubation (Table 2). Survivors required fewer vasopressors (1.4 vs 2.4, \( P = 0.0009 \)) for shorter durations (6 vs 9 days, \( P = 0.2411 \)) and spent significantly more days on the ventilator (16.5 vs 9 days, \( P = 0.0173 \)). Ventilator parameters differed in regard to positive end-expiratory pressure (PEEP) on days 1 and 3 (PEEP day 1: 12.6 vs 7.9 cm H\(_2\)O, 95% CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; PEEP, positive end-expiratory pressure; SD, standard deviation)

Table 1. Demographic characteristics and comorbidities by survival status (\( N = 56 \)) March 15–October 10, 2020

| Characteristic                      | Total cases, no. (%) | Survivors, no. (%) | Expired, no. (%) | \( P \)  |
|-------------------------------------|----------------------|--------------------|------------------|---------|
| Total                               | 56 (100)             | 14 (25)            | 42 (75)          | <0.0001 |
| Sex                                 |                      |                    |                  |         |
| Male                                | 30 (53.6)            | 4 (29)             | 26 (62)          | 0.0305  |
| Female                              | 26 (46.4)            | 10 (71)            | 16 (38)          | 0.0303  |
| Age (mean, SD)                      | 62.8 ± 14.4          | 59.5 ± 14.1        | 63.8 ± 14.2      | 0.3356  |
| Race                                |                      |                    |                  |         |
| White                               | 31 (55.4)            | 7 (50)             | 24 (57)          | 0.6415  |
| Black                               | 21 (37.5)            | 6 (43)             | 15 (36)          | 0.6326  |
| Other                               | 4 (7.1)              | 1 (7)              | 3 (7)            | 1.00    |
| BMI: median (IQR)                   | 31.8 (27.7–38.3)     | 34.9 (28.7–38.3)   | 31.3 (26.6–37.6) | 0.2225  |
| Comorbidities                       |                      |                    |                  |         |
| Hypertension                        | 45 (80.4)            | 12 (86)            | 33 (76)          | 0.7115  |
| Diabetes mellitus                   | 34 (60.7)            | 10 (71)            | 24 (57)          | 0.5287  |
| Cardiovascular disorders            | 27 (48.2)            | 4 (29)             | 23 (55)          | 0.1255  |
| Pulmonary disorders                 | 18 (32.1)            | 2 (14)             | 16 (38)          | 0.1846  |
| Malignancy                          | 10 (17.9)            | 1 (7)              | 9 (21)           | 0.4266  |
| Autoimmune disorders                | 4 (7.1)              | 1 (7)              | 3 (7)            | 1.00    |
| Multiple comorbidities: median (IQR)| 5 (4–7.7)            | 6 (4.75–6.25)      | 5 (3.75–8)       | 0.8537  |

Table 2. Patient parameters by survival status (\( N = 56 \)), March 15–October 10, 2020

| Parameters                          | Total cases | Survivors | Expired | 95% CI | \( P \)  |
|-------------------------------------|-------------|-----------|---------|--------|---------|
| Ventilator settings                 |             |           |         |        |         |
| PEEP cm H\(_2\)O, median, IQR      |             |           |         |        |         |
| Day 1                               | 9.2 (5.4–16.6) | 12.6 (7.7–20) | 7.9 (5.2–12.1) | 0.1373–6.722 | 0.0415  |
| Day 3                               | 10.2 (6.3–14.1) | 8.8 (5–12.5)   | 10.2 (7.2–14.3) | −4.903 to 1.324 | 0.2531  |
| FiO\(_2\) median, IQR              |             |           |         |        |         |
| Day 1                               | 100 (80–100)   | 80.2 (70–100)  | 100 (85–100)  | −19.22 to −0.7408 | 0.0348  |
| Day 3                               | 59 (40–80)     | 48 (40–60)    | 60 (45–87)     | −27.75 to −1.449 | 0.0304  |
| PaO\(_2\):FiO\(_2\), mmHg, median, IQR |       |           |         |        |         |
| Day 1                               | 66.5 (54.5–87.5) | 77.5 (56–116)  | 65 (52–81)     | −36.08 to 59.03 | 0.6305  |
| Day 3                               | 144 (97–212)   | 144 (127–213)  | 145 (84–199)   | −46.35 to 55.29 | 0.8601  |
| Vasopressor use, no. (%)            | 53 (94.6)     | 13 (93)     | 40 (95)      | 0.2481–4.154 | 1       |
| Duration, d, median (IQR)           | 8 (3–16)      | 6 (3–13)    | 9 (3–18)     | −9.679 to 2.490 | 0.2411  |
| No. agents/case, mean, SD           | 2 ± 1         | 1.4 ± 0.6   | 2.4 ± 0.9    | −1.478 to −0.4030 | 0.0009  |
| Other median (IQR)                  |             |           |         |        |         |
| Days prone                          | 2 (0–5)       | 1.5 (0–4)   | 2.5 (0–6)   | −5.748 to 1.748 | 0.2895  |
| Total ventilator days               | 10 (5–21)     | 16.5 (9–23) | 9 (4–17)    | 1.425–14.11 | 0.0173  |
| Preintubation hospital days         | 4 (1–8)       | 2 (0–3)    | 5 (1–8)    | −6.314 to 0.5523 | 0.0983  |
| Preintubation ICU days              | 1 (0–6)       | 0 (0–2)    | 2.5 (0–6)  | −5.899 to 0.8041 | 0.1334  |
CI 0.1373–6.722, \( P = 0.0415 \); PEEP day 3: 8.8 vs 10.2 cm H\(_2\)O, 95% CI –4.903 to 1.324, \( P = 0.2531 \); Table 2).

**Discussion**

This retrospective cohort study shows a high mortality in patients intubated in the ICUs of a community hospital system. Survivors had higher Pa\(\text{O}_2\)/Fi\(\text{O}_2\) ratios on the day of intubation (77.5 vs 65 mm H\(_g\), \( P = 0.6305 \)) and were intubated sooner than nonsurvivors (2 vs 5 days, \( P = 0.0983 \); Table 2). Although not statistically significant, our results represent clinical significance. A recently published study also reported improved outcomes in patients intubated earlier in their course.3

Although these survival data are worse than reported in a recent meta-analysis, which showed an adjusted case fatality rate of 56%, the results may be explained by the severity of hypoxia, presence of comorbidities at baseline, and average age (62.8 ± 14.4 years) in our cohort (Table 2).1 The median Pa\(\text{O}_2\)/Fi\(\text{O}_2\) ratio in our patient population was 66.5 mm H\(_g\) at the time of intubation, as opposed to 105 and 160 mm H\(_g\) in similar studies.4,5 In addition, the mortality rate of 75% was similar to the rate of >70% in patients older than 60 years in the meta-analysis by Lim et al.1

Earlier mechanical ventilation in survivors may be reflective of a stage when COVID-19-associated respiratory failure is more responsive to mechanical ventilation. Conversely, patients intubated earlier may be phenotypically different, manifesting more hypoxemia and dyspnea at an earlier stage of the disease. A recent clinical update describes two different phenotypes of respiratory failure in COVID-19. An “L” phenotype, which has higher compliance and more ground glass opacities versus dense consolidation and lower compliance seen in the “H” phenotype.6 Our cohort of survivors may have been representative of the L phenotype. Unfortunately, we are unable to establish this based on the information available.

Higher PEEP is noted to have been applied initially in survivors compared with nonsurvivors (12.6 vs 7.9 cm H\(_2\)O, \( P = 0.0415 \)). Owing to the retrospective design of this study, it is difficult to elucidate which factors led to higher PEEP at the outset in survivors, even though their Pa\(\text{O}_2\)/Fi\(\text{O}_2\) ratio was higher than that of nonsurvivors (77.5 vs 65 mm H\(_g\), \( P = 0.6305 \)). Because the usual practice in our ICU is to find optimal PEEP using driving pressures, it is plausible that higher PEEP could not be applied in nonsurvivors because of lower lung compliance.7 In this respect, our surviving patients do not fit the L phenotype because these patients are not described as being PEEP responsive.

The effect of more aggressive PEEP application in survivors can be seen on day 3 postintubation, by which time PEEP had been reduced to 8.8 cm H\(_2\)O in survivors versus 10.2 cm H\(_2\)O in nonsurvivors (\( P = 0.2531 \), and Fi\(\text{O}_2\) had been reduced to 48% vs 60% (\( P = 0.0304 \)). Although the Pa\(\text{O}_2\)/Fi\(\text{O}_2\) ratio on day 3 postintubation was similar between the two groups (144 vs 145 mm H\(_g\), \( P = 0.8601 \)), survivors maintained this ratio at a lower PEEP.

Survivors spent a significantly longer time on the ventilator than nonsurvivors. In this regard, it is notable that 32 of the 42 nonsurvivors (76%) underwent withdrawal of support as requested by family. This is likely related to the greater comparative severity of illness in these patients, coupled with a perception of poor outcomes that were pervasive during the pandemic.

**Conclusions**

This small retrospective study shows a high mortality rate in patients intubated for COVID-19–associated acute respiratory failure. We observed improved outcomes with earlier intubation in these patients. Based on the retrospective design of this study, we are unable to state whether the early intubation was coincidental, leading to improved outcomes or necessitated by phenotypic variations in some patients who decline more rapidly in terms of hypoxemia and dyspnea, leading to earlier intubation. This aspect of COVID-19 respiratory failure deserves further study.

**References**

1. Lim ZJ, Subramaniam A, Reddy MP, et al. Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. *Am J Respir Crit Care Med* 2021;203:54–66.
2. Babar I, Ekenna O, Clarkson M, et al. COVID-19 in a Mississippi community hospital. *South Med J* 2021;114:305–310.
3. Pandya A, Kaur NA, Sacher D, et al. Ventilatory mechanics in early vs late intubation in a cohort of coronavirus disease 2019 patients with ARDS: a single center’s experience. *Chest* 2021;159:653–656.
4. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* 2020;323:1574–1581.
5. Luo M, Cao S, Wei L, et al. Intubation, mortality, and risk factors in critically ill COVID-19 patients: a pilot study. *J Clin Anesth* 2020;67:10039.
6. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. *JAMA* 2020;323:2329–2330.
7. Amato M, Meade M, Slutsky A, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015;372:747–755.